Kandi Zhang1, Wenlong Yang2, Mingliang Zhang2, Yaping Sun2, Tiantian Zhang2, Junling Liu3, Junfeng Zhang2. 1. Department of Cardiology, No.9 People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, No.280, Mohe Road, Baoshan District, 201900 Shanghai, China, 201900 Shanghai, China. zhangkandi0916@163.com. 2. Department of Cardiology, No.9 People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, No.280, Mohe Road, Baoshan District, 201900 Shanghai, China, 201900 Shanghai, China. 3. Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Abstract
BACKGROUND: Reperfusion therapy is known to improve prognosis and limit myocardial damage after myocardial infarction (MI). The administration of antiplatelet drugs prior to percutaneous coronary intervention also proves beneficial to patients with acute MI (AMI). However, a good number of AMI patients do not receive reperfusion therapy, and it is not clear if they would benefit from antiplatelet pre-treatment. METHODS: Experimental C57BL/6 mice were randomly allocated to five groups: the sham group, control, post-treatment, pre-treatment, and pre- and post-treatment groups. Acetylsalicylic acid (15 mg/kg), clopidogrel (11 mg/kg), ticagrelor (27 mg/kg), and prasugrel (1.5 mg/kg) were intragastrically administered in the treatment groups. On day 7 post MI, cardiac function and cardiac fibrosis were evaluated using echocardiography and Masson's trichrome staining, respectively. Histopathological examinations were performed on tissue sections to grade inflammatory cell infiltration. Platelet inhibition was monitored by measuring thrombin-induced platelet aggregation. RESULTS: Left ventricular ejection fraction and fractional shortening improved significantly (p < 0.01) in the pre-treatment groups when compared to the post-treatment and control groups. A significant (p < 0.01) decrease in cardiac fibrosis was observed in the pre-treatment group, compared with the posttreatment and control groups. Inflammatory cell infiltration significantly decreased in the pre-treatment group compared with the control group (p < 0.05). Thrombin-induced platelet aggregation was significantly inhibited by antiplatelet drugs, but increased with the exposure to H2O2. CONCLUSIONS: In the absence of reperfusion therapy, pre-treatment with antiplatelet drugs successfully improved cardiac function, reduced cardiac fibrosis and inflammatory cell infiltration, and inhibited oxidative stress-induced platelet aggregation after MI in the mouse model.
BACKGROUND: Reperfusion therapy is known to improve prognosis and limit myocardial damage after myocardial infarction (MI). The administration of antiplatelet drugs prior to percutaneous coronary intervention also proves beneficial to patients with acute MI (AMI). However, a good number of AMI patients do not receive reperfusion therapy, and it is not clear if they would benefit from antiplatelet pre-treatment. METHODS: Experimental C57BL/6 mice were randomly allocated to five groups: the sham group, control, post-treatment, pre-treatment, and pre- and post-treatment groups. Acetylsalicylic acid (15 mg/kg), clopidogrel (11 mg/kg), ticagrelor (27 mg/kg), and prasugrel (1.5 mg/kg) were intragastrically administered in the treatment groups. On day 7 post MI, cardiac function and cardiac fibrosis were evaluated using echocardiography and Masson's trichrome staining, respectively. Histopathological examinations were performed on tissue sections to grade inflammatory cell infiltration. Platelet inhibition was monitored by measuring thrombin-induced platelet aggregation. RESULTS: Left ventricular ejection fraction and fractional shortening improved significantly (p < 0.01) in the pre-treatment groups when compared to the post-treatment and control groups. A significant (p < 0.01) decrease in cardiac fibrosis was observed in the pre-treatment group, compared with the posttreatment and control groups. Inflammatory cell infiltration significantly decreased in the pre-treatment group compared with the control group (p < 0.05). Thrombin-induced platelet aggregation was significantly inhibited by antiplatelet drugs, but increased with the exposure to H2O2. CONCLUSIONS: In the absence of reperfusion therapy, pre-treatment with antiplatelet drugs successfully improved cardiac function, reduced cardiac fibrosis and inflammatory cell infiltration, and inhibited oxidative stress-induced platelet aggregation after MI in the mouse model.
Authors: Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: John J McNeil; Rory Wolfe; Robyn L Woods; Andrew M Tonkin; Geoffrey A Donnan; Mark R Nelson; Christopher M Reid; Jessica E Lockery; Brenda Kirpach; Elsdon Storey; Raj C Shah; Jeff D Williamson; Karen L Margolis; Michael E Ernst; Walter P Abhayaratna; Nigel Stocks; Sharyn M Fitzgerald; Suzanne G Orchard; Ruth E Trevaks; Lawrence J Beilin; Colin I Johnston; Joanne Ryan; Barbara Radziszewska; Michael Jelinek; Mobin Malik; Charles B Eaton; Donna Brauer; Geoff Cloud; Erica M Wood; Suzanne E Mahady; Suzanne Satterfield; Richard Grimm; Anne M Murray Journal: N Engl J Med Date: 2018-09-16 Impact factor: 91.245
Authors: John J McNeil; Mark R Nelson; Robyn L Woods; Jessica E Lockery; Rory Wolfe; Christopher M Reid; Brenda Kirpach; Raj C Shah; Diane G Ives; Elsdon Storey; Joanne Ryan; Andrew M Tonkin; Anne B Newman; Jeff D Williamson; Karen L Margolis; Michael E Ernst; Walter P Abhayaratna; Nigel Stocks; Sharyn M Fitzgerald; Suzanne G Orchard; Ruth E Trevaks; Lawrence J Beilin; Geoffrey A Donnan; Peter Gibbs; Colin I Johnston; Barbara Radziszewska; Richard Grimm; Anne M Murray Journal: N Engl J Med Date: 2018-09-16 Impact factor: 91.245
Authors: Aldona Kubica; Agata Kosobucka; Piotr Niezgoda; Piotr Adamski; Katarzyna Buszko; Maciej Lesiak; Wojciech Wojakowski; Mariusz Gasior; Jarosław Gorący; Andrzej Kleinrok; Klaudiusz Nadolny; Eliano Navarese; Jacek Kubica Journal: BMJ Open Date: 2021-03-01 Impact factor: 2.692
Authors: Piotr Niezgoda; Malwina Barańska; Piotr Adamski; Łukasz Pietrzykowski; Michał Piotr Marszałł; Wojciech Wojakowski; Wiktor Kuliczkowski; Diana Gorog; Bernd Jilma; Klaudiusz Nadolny; Eliano Pio Navarese; Aldona Kubica; Jacek Kubica Journal: Cardiol J Date: 2021-10-13 Impact factor: 2.737
Authors: Abi Selvarajah; Anne H Tavenier; Enrico Fabris; Maarten A H van Leeuwen; Renicus S Hermanides Journal: J Clin Med Date: 2022-09-23 Impact factor: 4.964